Objective: The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase high-performance liquid chromatography method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir in bulk and tablet dosage forms.
INTRODUCTION
Hepatitis C virus (HCV) was found to be a commonly attacking disease to human beings and was increased day by day. The literature reveals that 72% of the patients were suffered from chronic HCV [1] . In early stage, 75-85% of the liver is persisted with the virus. These defects have been treated by the use of oral form of these combinational drugs, respectively [2] .
Sofosbuvir is an antiviral drug in the treatment of chronic HCV [3, 4] . It is chemically isopropyl(2S)-2-[(2R,3R,4R,5R)-5-(2,4dioxopyrimidin-1-yl)-4-Fluoro-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propionate [5, 6] . Sofosbuvir is a white-to-white crystalline powder with a molecular formula of C 22 H 29 FN 3 O 9 P and molecular weight of 529.4 g/mole. Its chemical structure is given in Fig. 1 . Velpatasvir is an NS5A inhibitor which acts on HCV. Velpatasvir is chemically Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl) amino]-2-phenylacetyl]-(methoxymethyl)-2-pyrrolidinyl]-1Himidazol-4-yl}-1,-11-dihydroisochromeno[4', 3: ' 6, 7] naphtha [1,2-d] imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl} carbonate [7, 8] . It is a white to light yellow solid powder with a molecular formula of C 49 H 54 N 8 O 8 and a molecular weight of 883.02 g/ mole. Its chemical structure is given in Fig. 2 .
Voxilaprevir is also a protease inhibitor and acts as a transporter of polypeptide. It is chemically (1R,18R,20R,24S,27S,28S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclo propyl)sulfonyl]carbamoyl} cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26tetraazapentacyclo dioxanonacosa-3(12),4,6, 8,10-pentaene-27-carboxamide [9, 10] . It is a white to light yellow solid powder with a molecular formula C 40 H 52 F 4 N 6 O 9 S and a molecular weight of 868.94 g/mole. Its chemical structure is given in Fig. 3 . The literature survey reveals that a very few spectroscopic and liquid chromatographic procedures have been reported for the determination of sofosbuvir, velpatasvir, and voxilaprevir by ultraviolet (UV) and high-performance liquid chromatography (HPLC) [11, 12] . Therefore, there is a need to develop a rapid, sensitive reversed-phase (RP)-HPLC method for simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir in bulk and pharmaceutical dosage form.
EXPERIMENTAL

Materials and methods
The reference samples of sofosbuvir, velpatasvir, and voxilaprevir were provided as a gift sample from spectrum Pharma Research Solutions, Hyderabad. VOSEVI tablets labeled to contain sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg were purchased from the local pharmacy store. HPLC grade acetonitrile was purchased from Ramkem, Haryana, India. Orthophosphoric acid was purchased from Fischer Scientific, Mumbai, India. HPLC grade water was prepared using Millipore Milli-Q water purification system used throughout the process.
Preparation of sample and standard solution
Ten tablets were accurately weighed and crushed to powder in a motor using pestle and weight equivalent to one tablet was transferred to 100 ml volumetric flask, about 50 ml of diluents was added and sonicated for 25 min, further the volume mark up with diluents and filtered. From above solution, 1.0 ml of filtered sample stock solution was transferred into 10 ml volumetric flask and made up with diluents.
Method validation
The developed method for sofosbuvir, velpatasvir, and voxilaprevir was validated for parameters such as system suitability, linearity, precision, accuracy, robustness, limit of detection (LOD), limit of quantification (LOQ), and solution stability as per ICH guidelines.
RESULTS AND DISCUSSION
Optimized chromatographic conditions
After systematic and detailed study of the various parameters involved in the method, the following conditions were employed:
Instrument
Waters 2695 high-performance liquid chromatography 
System suitability
Six replicates of the working standard solution were prepared and injected to carry out system suitability parameters such as retention time, peak area, United States Pharmacopeia (USP) plate count, USP resolution, and USP tailing. The system suitability parameters are given in Table 1 and system suitability chromatograms are given in Fig. 5 .
Specificity
It is the ability to unequivocally assess the analyte in the presence of components that may be expected to be present. Typically, these might be including impurities, degradants, or matrix.
Blank placebo interferences
A study to establish the interferences of blank and placebo was conducted. Analysis was performed on solution placebo and formulation as per the test method. Chromatograms of blank, placebo, and formulation solution showed no peaks at the retention time of sofosbuvir, velpatasvir, and voxilaprevir peaks. The chromatograms of sofosbuvir, velpatasvir, voxilaprevir of standard, formulation, blank, and placebo using the proposed method are shown in Figs. 6-9.
Linearity
Diluting aliquots of 0.25, 0.5, 0.75, 1.0, 1.25, and 1.5 ml of standard working solution were pipette out from the standard stock solution of concentration 100 µg/ml of sofosbuvir, 25 µg/ml of velpatasvir, and 25 µg/ml of voxilaprevir and these diluted up to mark with diluents. Such that, the final concentrations were in the range of 100-600 µg/ml sofosbuvir, 25-150 µg/ml velpatasvir, and 25-150 µg/ml voxilaprevir. The calibration standard solution of sofosbuvir, velpatasvir, and voxilaprevir was injected using a 5 µl injector and the chromatograms were recorded at 220 nm and calibration curve was constructed by plotting the peak area versus drug concentration. The linearity data are presented in Figs. 10-12 and Table 2 , and all parameter results are within the limits.
LOD and LOQ
A study to establish the LOD and LOQ for sofosbuvir, velpatasvir, and voxilaprevir was conducted. Series of very dilute LOD and LOQ solutions were prepared as per the test method and injected triplicate into the HPLC system. The LOD and LOQ were established based on signalto-noise ratio. LOD was established by identifying the concentration which given s/n ratio 3, whereas LOQ was established by identifying the concentration which gives s/n ratio of about 10. The sensitivity results are shown in Table 3 . Chromatograms of LOD and LOQ values are given in Table 3 . 
Precision
It is an analytical method and is defined as agreement between the replicate measurements of the sample. It is expressed as the percentage coefficient of correlation or relative standard deviation (RSD) of the replicate measurements. 
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System precision (intraday precision/repeatability)
Working standard preparation of 5 µl solution was injected 6 times into the HPLC system and chromatograms were obtained. %RSD of the peak area was calculated. The results of system precision studies are shown in Table 4 .
Method precision
Working sample solutions of 5 µl were injected six preparations into the HPLC system and chromatograms were obtained. The %RSD of the assay result of six preparations was calculated. The results obtained for assay are presented in Table 5 .
Intermediate precision/interday precision
Working standard preparation of 5 µl was injected 6 times test preparations into the HPLC system and chromatograms were obtained. %RSD was determined for peak areas. The results of intermediate precision study are reported in Table 6 .
Accuracy
A known amount of sofosbuvir, velpatasvir, and voxilaprevir at each three concentration levels 50%, 100%, and 150% was added to a preanalyzed sample solution and injected in triplicate at each level into the HPLC system. The mean percentage recovery of sofosbuvir, velpatasvir, Tables 7-9 .
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Robustness
Working standard solution prepared as per test method was injected into the HPLC system at variable conditions such as flow rate at ±0.1 ml/min, mobile organic phase composition by ±10%, and column temperature by ±5°C. The results of robustness study are shown in Tables 10-12 .
Forced degradation studies
Acid degradation studies
To 1 ml of standard stock solution of sofosbuvir, velpatasvir, and voxilaprevir, 1 ml of 1 N hydrochloric acid was added and sonicated for 30 min at 60°C. The resultant solution was diluted to obtain 400 µg/ ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solution was injected into the system and the chromatograms were recorded to assess the stability of the sample (Fig. 13 ).
Base degradation studies
To 1 ml of standard stock solution of sofosbuvir, velpatasvir, and voxilaprevir, 1 ml of 1 N sodium hydroxide was added and sonicated for 30 min at 60°C. The resultant solution was diluted to obtain 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solution was injected into the system and the chromatograms were recorded to assess the stability of sample (Fig. 14) .
Oxidation
To 1 ml of standard stock solution of sofosbuvir, velpatasvir, and voxilaprevir, 1 ml of 20% hydrogen peroxide was added separately. The solutions were kept for 30 min at 60°C. For HPLC study, the resultant solution was diluted to obtain 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solution was injected into the system and the chromatogram was recorded to assess the stability of sample ( Fig. 15 and Tables 13-15) .
Dry heat degradation studies
The standard drug solution was placed in oven at 105°C for 6 h to study dry heat degradation. For HPLC study, the resultant solution was diluted to obtain 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solutions were injected into the system and the chromatograms were recorded to assess the stability of the sample (Fig. 16 ).
Photostability studies
The photochemical stability of the drug was also studied by exposing the 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions to UV light by keeping the beaker in UV chamber for 3 days or 200 Watt h/m 2 in photostability chamber. For HPLC study, the resultant solution was diluted to obtain 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solutions were injected into the system and the chromatograms were recorded to assess the stability of sample. 
Neutral degradation studies
Stress testing under neutral conditions was studied by refluxing the drug in water for 6 h at a temperature of 60°C. For HPLC study, the resultant solution was diluted to 400 µg/ml, 100 µg/ml, and 100 µg/ ml solutions and 5 µl solutions were injected into the system and the
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chromatograms were recorded to assess the stability of the sample (Fig. 17 ).
Neutral degradation studies
Stress testing under neutral conditions was studied by refluxing the drug in water for 6 h at a temperature of 60°C. For HPLC study, the resultant solution was diluted to 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solutions were injected into the system and the chromatograms were recorded to assess the stability of the sample (Fig. 18 ).
Proposed procedures for marketed pharmaceutical formulation
The commercial tablet (VOSEVI) was analyzed separating by injecting 5 µl of standard and sample preparation solutions injected 6 times into Padmini and Sankar the HPLC system and chromatograms were recorded. The amount of the drug present in marketed tablets was calculated by comparing the peak area of standard and sample. The % assay of sofosbuvir, velpatasvir, and voxilaprevir was found to be 99-100%. The typical chromatograms of standard and sample solutions using the proposed method are shown in Table 16 .
CONCLUSION
A simple, accurate, precise, and robust method was developed for the stability-indicating RP-HPLC method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir in tablet dosage forms. Retention time of sofosbuvir, velpatasvir, and voxilaprevir were found to be 2.213 min, 2.568 min, and 2.917 min. %RSD of the sofosbuvir, velpatasvir, and voxilaprevir was found to be 0.2 µg/ml, 0.9 µg/ml, and 0.6 µg/ml, respectively. Percentage recovery was obtained as 100.01%, 99.91%, and 100.26% for sofosbuvir, velpatasvir, and voxilaprevir, respectively. System precision values were found to be 0.3 µg/ml, 0.8 µg/ml, and 0.8 µg/ml, and method precision values were found to be 0.3 µg/ml, 0.8 µg/ml, and 0.6 µg/ml. LOD and LOQ values obtained from regression equations of sofosbuvir, velpatasvir, and voxilaprevir were 0.7 µg/ml, 0.17 µg/ml, 0.23 µg/ml, 2.32 µg/ml, 0.53 µg/ml, and 0.70 µg/ml. Regression equation of sofosbuvir y=4072.4x+1076.3, velpatasvir y=3069.8x+2589.8, and voxilaprevir y=3228x+974.39, respectively. Stress degradation studies were found to be within limits. Retention times were decreased and run time was decreased. Hence, the method development was simple and economical that can be adopted in regular quality control analysis test in pharmaceutical industries.
